Genervon Biopharmaceuticals is focused on a novel approach to drug development, particularly for neurodegenerative diseases, by emphasizing multi-target drug development. The company has identified a naturally occurring regulator known as motoneuronotrophic factor (MNTF), which plays a crucial role in the development of the human nervous system. Building on this discovery, Genervon has developed GM6, a cationic, cell-penetrating peptide analog of MNTF. This innovative peptide is designed to effectively cross the blood-brain barrier, demonstrating safety and tolerability in clinical studies. GM6 has shown the ability to modulate key biomarkers and multiple defective pathways associated with various neurodegenerative disorders, including ALS, Parkinson's disease, Alzheimer's disease, and multiple sclerosis.

The efficacy of GM6 in neuroprotection has been substantiated through extensive preclinical testing, where it has demonstrated significant improvements in neuron survival against toxic cerebrospinal fluid in models of neurodegeneration. GM6's properties include a favorable brain-to-plasma ratio and stability under various conditions, making it a promising candidate for treating complex neurological conditions. Genervon holds numerous patents related to the composition and therapeutic applications of MNTF and its analogs, reinforcing its commitment to advancing innovative treatments for patients suffering from debilitating neurodegenerative diseases.

United States

Genervon is a clinical-stage biopharmaceutical company focused on novel treatments for neurodegenerative diseases and disorders. Genervon holds many patents worldwide for MNTF, GM6 and related compounds and processes and has obtained an orphan-drug designation and a fast-track designation for GM6 to treat ALS. Genervon is currently planning late-stage clinical trials for GM6 for ALS, PD, AD and MS indications. Genervon is actively seeking partners to help advance GM6 from a development-stage drug candidate to a marketable therapy for the many victims of neurodegenerative diseases and disorders that desperately need help.

Genervon Biopharmaceuticals

Company Details